Ratings by Rodman & Renshaw (Seema Sheoran)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/21/2026 | Eledon Pharamceuticals | ELDN | New Coverage | Buy (N/A) |
3.86 (3.74) |
-3.11% | Details | |
| 6/3/2026 | Neurogene | NGNE | New Coverage | Buy (N/A) |
26.14 (35.57) |
36.07% | Details | |
| 4/14/2026 | CAMP4 Therapeutics Corp | CAMP | New Coverage | Buy (N/A) |
4.64 (3.01) |
-35.13% | Details | |
| 4/2/2026 | SAB Biotherapeutics | SABS | New Coverage | Buy (N/A) |
3.87 (3.58) |
-7.49% | Details | |
| 3/26/2026 | Enanta Pharmaceuticals | ENTA | New Coverage | Buy (N/A) |
12.17 (12.95) |
6.41% | Details | |
| 3/26/2026 | Sagimet Biosciences Inc | SGMT | New Coverage | Buy (N/A) |
4.62 (7.01) |
51.73% | Details |
